ReviewEuropean urology2018
Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).
Review in European urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 310 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-parameter Magnetic Resonance Imaging for Early Evaluation of the Efficacy of Neoadjuvant Chemotherapy With Modified GC Regimen for Urothelial Carcinoma
Prospective Multi-center Clinical Study on the Application Value of Artificial Intelligence in MRI Precision Diagnosis and Treatment of Bladder Cancer
Clinical Utility of Vesical Imaging Report and Data System (VI-RADS) in Diagnosis of Muscle Invasive Bladder Cancer
Validity of Parametric MRI Using VIRAD Scoring in the Diagnosis of Cancer Bladder
Who cites it
310 citing papers in PubMed, 5 syntheses or guidelines pooled it, 613 citations in OpenAlex.
- The role of MRI in detection and staging of upper urinary tract cancer: a systematic review of the literature.Frontiers in oncology · 2026Pooled it
- Diagnostic performance of artificial intelligence in detecting bladder carcinoma.World journal of urology · 2025Pooled it
- Diagnostic Performance and Interobserver Agreement of the Vesical Imaging-Reporting and Data System (VI-RADS) in Bladder Cancer Staging: A Systematic Review.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Diagnostic Accuracy of Contrast-Enhanced Ultrasound (CEUS) in the Detection of Muscle-Invasive Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis.Current oncology (Toronto, Ont.) · 2024Pooled it
- Inter-reader reliability of the vesical imaging-reporting and data system (VI-RADS) for muscle-invasive bladder cancer: a systematic review and meta-analysis.Abdominal radiology (New York) · 2022Pooled it
- Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Real-world outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial.BJU international · 2025Trial
- Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT.Health technology assessment (Winchester, England) · 2024Trial
- Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.Nature medicine · 2023Trial
- Feasibility of Early Evaluation for the Recurrence of Bladder Cancer after Trans-Urethral Resection: A Comparison between Magnetic Resonance Imaging and Multidetector Computed Tomography.Tomography (Ann Arbor, Mich.) · 2022Trial
- Clinical indicators combined with spectral CT in differentiating non-muscle-invasive bladder urothelial carcinoma from cystitis glandularis.Abdominal radiology (New York) · 2026Article
- Impact of VI-RADS quality score on VI-RADS diagnostic performance for muscle invasion: the role of tumor size and reader experience.European radiology · 2026Article
- Reproducibility and diagnostic performance of ADC for assessing response to neoadjuvant immunotherapy in muscle-invasive bladder cancer: a multi-ROI comparison analysis from the phase-Ib NABUCCO trial.Insights into imaging · 2026Article
- Editorial for "A Quantitative Modification of VI-RADS for Bladder Cancer at the Ureteral Orifice: A Reader Study on MRI With Varying Experience Levels".Journal of magnetic resonance imaging : JMRI · 2026Article
- Interobserver agreement of non-parallel transmission technology zoomed-diffusion-weighted imaging (DWI) for ordinal biparametric Vesical Imaging-Reporting and Data System (VI-RADS)-based scoring in bladder cancer lesions ≥1 cm.Quantitative imaging in medicine and surgery · 2026Article
- A Quantitative Modification of VI-RADS for Bladder Cancer at the Ureteral Orifice: A Reader Study on MRI With Varying Experience Levels.Journal of magnetic resonance imaging : JMRI · 2026Article
- Artificial intelligence and radiomics in bladder cancer MRI: a scoping review of applications, performance, and barriers to clinical translation.Abdominal radiology (New York) · 2026Article
- A two-stage foundation model for bladder tumor segmentation: An international multi-site studyEuropean journal of radiology artificial intelligence · 2026Article
- The Stalk Sign in Bladder Cancer: CEUS Versus MRI.Diagnostics (Basel, Switzerland) · 2026Article
250 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
18 authors at 15 institutions in 7 countries.
Funding
Abstract
contextManagement of bladder cancer (BC) is primarily driven by stage, grade, and biological potential. Knowledge of each is derived using clinical, histopathological, and radiological investigations. This multimodal approach reduces the risk of error from one particular test, but may present a staging dilemma when results conflict. Multiparametric magnetic resonance imaging (mpMRI) may improve patient care through imaging of the bladder with better resolution of the tissue planes than computed tomography and without radiation exposure.
objectiveTo define a standardized approach to imaging and reporting mpMRI for BC, by developing a VI-RADS score. EVIDENCE ACQUISITION: We created VI-RADS (Vesical Imaging-Reporting And Data System) through consensus using existing literature. EVIDENCE SYNTHESIS: We describe standard imaging protocols and reporting criteria (including size, location, multiplicity, and morphology) for bladder mpMRI. We propose a five-point VI-RADS score, derived using T2-weighted MRI, diffusion-weighted imaging, and dynamic contrast enhancement, which suggests the risks of muscle invasion. We include sample images used to understand VI-RADS.
conclusionsWe hope that VI-RADS will standardize reporting, facilitate comparisons between patients, and in future years, will be tested and refined if necessary. While we do not advocate mpMRI for all patients with BC, this imaging may compliment pathology or reduce radiation-based imaging. Bladder mpMRI may be most useful in patients with non-muscle-invasive cancers, in expediting radical treatment or for determining response to bladder-sparing approaches. PATIENT SUMMARY: Magnetic resonance imaging (MRI) scans for bladder cancer are becoming more common and may provide accurate information that helps improve patient care. Here, we describe a standardized reporting criterion for bladder MRI. This should improve communication between doctors and allow better comparisons between patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.